Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

Peer Review reports

Original Submission
13 Jul 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
7 Aug 2022	Reviewed	Reviewer Report - Niranjan J. Sathianathen
14 Aug 2022	Reviewed	Reviewer Report
22 Aug 2022	Author responded	Author comments - Mikio Sugimoto
Resubmission - Version 4
22 Aug 2022	Submitted	Manuscript version 4
26 Aug 2022	Author responded	Author comments - Mikio Sugimoto
Resubmission - Version 5
26 Aug 2022	Submitted	Manuscript version 5
Publishing
29 Aug 2022	Editorially accepted
14 Sep 2022	Article published	10.1186/s12894-022-01096-3

Back to article page